关注
Cyrielle Fougeroux
Cyrielle Fougeroux
Post-doc in immunology, Copenhagen university
在 sund.ku.dk 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
C Fougeroux, L Goksøyr, M Idorn, V Soroka, SK Myeni, R Dagil, ...
Nature Communications 12 (1), 324, 2021
962021
Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells
I Bagdonaite, AJ Thompson, X Wang, M Søgaard, C Fougeroux, M Frank, ...
Viruses 13 (4), 551, 2021
682021
Future prospects for the development of cost-effective adenovirus vaccines
C Fougeroux, PJ Holst
International journal of molecular sciences 18 (4), 686, 2017
562017
Quality control of microbiota metagenomics by k-mer analysis
F Plaza Onate, JM Batto, C Juste, J Fadlallah, C Fougeroux, D Gouas, ...
BMC genomics 16, 1-10, 2015
342015
Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants
L van Oosten, JJ Altenburg, C Fougeroux, C Geertsema, F van den End, ...
MBio 12 (5), 10.1128/mbio. 01813-21, 2021
302021
Identification and characterization of serovar-independent immunogens in Actinobacillus pleuropneumoniae
F Antenucci, C Fougeroux, JT Bossé, Z Magnowska, C Roesch, ...
Veterinary research 48, 1-12, 2017
262017
In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae
F Antenucci, C Fougeroux, A Deeney, C Ørskov, A Rycroft, PJ Holst, ...
Veterinary research 49, 1-11, 2018
252018
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
MJ Smit, AF Sander, MBPA Ariaans, C Fougeroux, C Heinzel, R Fendel, ...
The Lancet Microbe 4 (3), e140-e148, 2023
152023
The potential of adenoviral vaccine vectors with altered antigen presentation capabilities
L Neukirch, C Fougeroux, AMC Andersson, PJ Holst
Expert review of vaccines 19 (1), 25-41, 2020
152020
Modified MHC Class II–Associated Invariant Chain Induces Increased Antibody Responses Against Plasmodium Falciparum Antigens After Adenoviral Vaccination
C Fougeroux, L Turner, AM Bojesen, T Lavstsen, PJ Holst
The Journal of Immunology 202 (8), 2320-2331, 2019
152019
An S1-nanoparticle vaccine protects against SARS-CoV-2 challenge in K18-hACE2 mice
L van Oosten, K Yan, DJ Rawle, TT Le, JJ Altenburg, C Fougeroux, ...
Journal of Virology 96 (14), e00844-22, 2022
72022
Capsid-like particles decorated with the SARS-CoV-2 receptorbinding domain elicit strong virus neutralization activity. Nat Commun 12: 324
C Fougeroux, L Goksøyr, M Idorn, V Soroka, SK Myeni, R Dagil, ...
72021
Replication deficient human adenovirus vector serotype 19a/64: Immunogenicity in mice and female cynomolgus macaques
E Ragonnaud, S Schroedel, S Mariya, D Iskandriati, J Pamungkas, ...
Vaccine 36 (41), 6212-6222, 2018
62018
SARS-CoV-2 RBD-specific antibodies induced early in the pandemic by natural infection and vaccination display cross-variant binding and inhibition
MR Walker, D Podlekareva, S Johnsen, B Leerhøy, C Fougeroux, ...
Viruses 14 (9), 1861, 2022
42022
Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozyme
FG Martinez, RA Zielke, CE Fougeroux, L Li, AF Sander, AE Sikora
Infection and Immunity 91 (12), e00245-23, 2023
32023
Freeze-drying of a capsid virus-like particle-based platform allows stable storage of vaccines at ambient temperature
KL Aves, CM Janitzek, CE Fougeroux, TG Theander, AF Sander
Pharmaceutics 14 (6), 1301, 2022
32022
Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021
E Lyimo, C Fougeroux, A Malabeja, J Mbwana, PM Hayuma, E Liheluka, ...
BMC Infectious Diseases 22 (1), 846, 2022
22022
Site-Specific O-Glycosylation Analysis of SARS-CoV-2 Spike Protein Produced in Insect and Human Cells. Viruses 2021, 13, 551
I Bagdonaite, AJ Thompson, X Wang, M Søgaard, C Fougeroux, M Frank, ...
s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021
22021
Nucleic acid vaccines
AFS Bertelsen, MA Nielsen, L Goksøyr, CE Fougeroux, WA De Jongh
US Patent App. 18/257,554, 2024
2024
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP …
F Ruzzi, L Scalambra, MS Semprini, OM Pittino, C Cappello, S Angelicola, ...
European Journal of Cancer 200, 2024
2024
系统目前无法执行此操作,请稍后再试。
文章 1–20